EUVIMEDEUVIMED entdecken
Crossref

Class I Recalls of Cardiovascular Devices Between 2013 and 2022

Claudia See iD, Maryam Mooghali iD, Sanket S Dhruva iD, Joseph S Ross iD, Harlan M Krumholz iD, Kushal T Kadakia

Annals of Internal Medicine · 2024

DOI: 10.7326/annals-24-00724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Claudia See und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, San Francisco, California (C.S.). Hauptthemen laut MEDLINE: Medical Device Recalls, United States Food and Drug Administration. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiovascular devices account for one third of all Class I recalls, the U.S. Food and Drug Administration's (FDA) most severe designation, indicating a reasonable probability of "serious adverse health consequences or death." Understanding recalls and their causes is important for patient safety. OBJECTIVE: To characterize Class I recalls of cardiovascular devices and the clinical evidence supporting authorization. DESIGN: In this cross-sectional study, cardiovascular device recalls from 1 January 2013 through 31 December 2022 were identified using the FDA's annual log. Information about devices was extracted from publicly available FDA decision summaries. SETTING: The FDA Medical Device Recalls database. PARTICIPANTS: Cardiovascular devices with Class I recalls. MEASUREMENTS: Recalls were characterized by their causes and scope. Devices were characterized by their regulatory history (product code, special designations) and clinical evidence (premarket testing, postmarket surveillance). Clinical studies were analyzed for quality, including end point selection (clinical vs. surrogate, use of composites). RESULTS: From 2013 to 2022, there were 137 Class I recall events affecting 157 unique cardiovascular devices, of which 112 (71.3%) were moderate-risk 510(k) devices and 45 (28.7%) were high-risk premarket approval (PMA) devices. Recalls affected a median of 7649 units (IQR, 953 to 28 446) and were most commonly attributed to device design (43 [31.4%]). Forty-two (26.8%) devices had multiple Class I recalls. Thirty (19.1%) devices underwent premarket clinical testing (7 [6.2%] 510(k) devices, 17 [85.0%] PMA devices, and 6 [24.0%] PMA supplement devices). Most studies used surrogate (27 [79.4%]) and composite (24 [70.6%]) measures as primary end points. Twenty-two (48.9%) PMA devices had required postapproval studies, with 14 reporting delays. No 510(k) devices were subject to postmarket surveillance. LIMITATION: Details about clinical testing may be missing from FDA summaries. CONCLUSION: Cardiovascular devices with Class I recalls were infrequently subjected to premarket or postmarket testing, with recalls affecting thousands of patients annually. PRIMARY FUNDING SOURCE: None.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical Device RecallsUnited States Food and Drug AdministrationCross-Sectional StudiesUnited StatesHumansProduct Surveillance, PostmarketingDevice ApprovalEquipment FailureEquipment Safety

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Francisco, San Francisco, California (C.S.).
  • Section of General Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut (M.M.).
  • Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, and Section of Cardiology, Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California (S.…
  • Section of General Medicine, Department of Medicine, Yale School of Medicine, and Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut (J.S.R.).
  • Department of Health Policy and Management, Yale School of Public Health; Center for Outcomes Research and Evaluation, Yale New Haven Hospital; and Section of Cardiovascular Medicine, Department of Internal Medicine, Ya…
  • Harvard Medical School, Boston, Massachusetts (K.T.K.).

ORCID-Profile: Claudia See, Maryam Mooghali, Sanket S Dhruva, Joseph S Ross, Harlan M Krumholz

Zitieren

APA

See, C., Mooghali, M., Dhruva, S. S., Ross, J. S., Krumholz, H. M., & Kadakia, K. T. (2024). Class I Recalls of Cardiovascular Devices Between 2013 and 2022. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-00724

Vancouver

See C, Mooghali M, Dhruva SS, Ross JS, Krumholz HM, Kadakia KT. Class I Recalls of Cardiovascular Devices Between 2013 and 2022. Annals of Internal Medicine. 2024. doi:10.7326/annals-24-00724

BibTeX
@article{See2024,
  author = {See, Claudia and Mooghali, Maryam and Dhruva, Sanket S and Ross, Joseph S and Krumholz, Harlan M and Kadakia, Kushal T},
  title = {Class I Recalls of Cardiovascular Devices Between 2013 and 2022},
  journal = {Annals of Internal Medicine},
  year = {2024},
  doi = {10.7326/annals-24-00724}
}
Kostenlos starten →